Business
Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025
24-month follow-up data from randomized Phase I part of the Phase I/II trial of TG4050 in resected locally advanced head and neck cancer selected for rapid oral presentationat ASCO on June 1st, 2025 Strasbourg, France, May 22, 2025, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces that it will present two-year disease-free survival (DFS) data from all patients in the randomized Ph
About this update from Transgene Sa
[{"type":"image","alt":"Transgene S.A.","displaySize":"","headline":null,"caption":"Transgene S.A.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":87,"url":"https://media.zenfs.com/en/globenewswire.com/79050c8f8969c772cb7cac9096afeefe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/57TyJq_DWnWiO0RrrrQXIg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/79050c8f8969c772cb7cac9096afeefe","width":300,"height":87}},"lazy":false},{"type":"text","content":"24-month follow-up data from randomized Phase I part of the Phase I/II trial of TG4050 in resected locally advanced head and neck cancer selected for rapid oral presentationat ASCO on June 1st, 2025","length":200,"tagName":"p","attribs":{}},{"type":"text","content":"Strasbourg, France, May 22, 2025, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces that it will present two-year disease-free survival (DFS) data from all patients in the randomized Phase I part of the trial of its individualized neoantigen therapeutic cancer vaccine TG4050. The data will be shared during a rapid oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago from May 30 to June 3, 2025.","length":575,"tagName":"p"},{"type":"text","content":"TG4050 is a viral vector-based immunotherapy based on Transgene’s myvac® platform and powered by NEC’s cutting-edge AI capabilities designed to optimize antigen selection.TG4050 is being evaluated in a randomized multicenter Phase I/II trial as a single agent in the adjuvant treatment of HPV-negative head and neck cancers (NCT04183166). Based on promising Phase I data, Transgene and partner NEC have advanced the joint development of TG4050 in this indication with a Phase II extension of the trial, which is currently enrolling patients.","length":547,"tagName":"p"},{"type":"text","content":"Key data to be presented include:","length":33,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Safety in locally advanced HPV-negative resectable head and neck squamous cell carcinoma (HNSCC),","length":97,"tagName":"p"}]},{"val":[{"type":"text","content":"Disease free survival after 2-year follow-up,","length":45,"tagName":"...